NYSEARCA:XPH SPDR S&P Pharmaceuticals ETF (XPH) Price, Holdings, & News $72.81 -0.76 (-1.03%) As of 04:10 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartDividendHoldingsNews and TrendsOwnershipRatingsShort Interest About SPDR S&P Pharmaceuticals ETF (NYSEARCA:XPH) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get XPH alerts:Sign Up Key Stats Today's Range$72.60▼$73.5050-Day Range$60.58▼$74.0652-Week Range$45.80▼$74.35Volume61,692 shsAverage Volume89,542 shsMarket Capitalization$524.23 millionAssets Under Management$591.72 millionDividend Yield0.45%Net Expense Ratio0.35%Aggregate RatingModerate Buy ETF Overview SPDR S&P Pharmaceuticals ETF (the Fund) seeks to replicate as closely as possible the total return performance of the S&P Pharmaceuticals Select Industry Index. The S&P Pharmaceuticals Select Industry Index represents the pharmaceuticals sub-industry portion of the S&P Total Markets Index. The S&P TMI tracks all the United States common stocks listed on the New York Stock Exchange, American Stock Exchange, National Association of Securities Dealers Automated Quotation (NASDAQ) National Market and NASDAQ Small Cap exchanges. The Fund invests substantially all, but at least 80%, of its total assets in the securities comprising the Index. In addition, the Fund may invest in equity securities that are not included in the Index, cash and cash equivalents or money market instruments, such as repurchase agreements and money market funds. The Pharmaceuticals Index is a modified equal weight index. SSgA Funds Management, Inc. is the Fund's investment advisor. Read More SPDR S&P Pharmaceuticals ETF ExpensesTypeXPHHealth Care ETFsEquity ETFsNYSEARCA ETFsAll ETFsManagement Fee0.35%0.55%0.57%0.51%0.53%Other Expenses0.00%0.52%0.53%0.60%0.54%Total Expense0.35%0.76%0.75%0.75%0.73%Fee Waiver0.00%-0.85%-0.67%-0.77%-0.68%Net Expense0.35%0.58%0.63%0.57%0.60% Receive XPH Stock News and Ratings via Email Sign-up to receive the latest news and ratings for SPDR S&P Pharmaceuticals ETF and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. XPH ETF News HeadlinesXPH: Dividendenhistorie, Rendite und Ex-Dividenden-TagAugust 23 at 12:44 PM | de.investing.comXPH vs PJP: Which Pharma ETF Offers Better ValueAugust 17, 2026 | fool.comThe retirement stock I'd buy before Nvidia todayIn 2014, Marc Chaikin pointed readers toward Nvidia. Now the 60-year Wall Street veteran and creator of the Chaikin Money Flow indicator has a new top retirement pick. The company holds three fast-growing businesses -- including an autonomous vehicle unit and a streaming service with 10x Netflix's reach -- any of which could be spun off in the next 12 to 24 months. It also pays a dividend, a rarity among high-growth AI names. Chaikin lays out the full case in a new free presentation, no email or credit card required.August 26 at 1:00 AM | Chaikin Analytics (Ad)State Street SPDR S&P Pharmaceuticals ETF (XPH)July 31, 2026 | finance.yahoo.comPharmaceuticals still a defensive play amid AI and geopolitical anxieties – analystJuly 21, 2026 | seekingalpha.comSPDR S&P Pharmaceuticals ETF declares quarterly distribution of $0.0590June 22, 2026 | msn.comSee More Headlines XPH ETF - Frequently Asked Questions How have XPH shares performed this year? SPDR S&P Pharmaceuticals ETF's stock was trading at $56.01 on January 1st, 2026. Since then, XPH shares have increased by 30.4% and is now trading at $73.06. Who are SPDR S&P Pharmaceuticals ETF's major shareholders? SPDR S&P Pharmaceuticals ETF's top institutional shareholders include Avior Wealth Management LLC (0.19%), Ameritas Advisory Services LLC (0.07%) and TD Waterhouse Canada Inc. (0.04%). How do I buy shares of SPDR S&P Pharmaceuticals ETF? Shares of XPH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of SPDR S&P Pharmaceuticals ETF own? Based on aggregate information from My MarketBeat watchlists, some other companies that SPDR S&P Pharmaceuticals ETF investors own include NVIDIA (NVDA), Pfizer (PFE), Adobe (ADBE), Applied Materials (AMAT), Chevron (CVX), JPMorgan Chase & Co. (JPM) and Meta Platforms (META). Fund Details IssuerSSgA Fund NameSPDR S&P Pharmaceuticals ETF Tax ClassificationRegulated Investment Company Stock ExchangeNYSEARCACurrent SymbolNYSEARCA:XPH Inception Date6/19/2006 Fund ManagerMichael Feehily, Karl Schneider, Keith Richardson Webwww.spdrs.com Phone+1-617-6644738Fund Focus Asset ClassEquity BenchmarkS&P Pharmaceuticals Select Industry Index CategorySector FocusHealth Care Development LevelDeveloped Markets RegionNorth America Number of Holdings81 Fund Statistics Assets Under Management$591.72 million Average Daily Volume$114.28 thousand Discount/Premium0.07% Administrator, Advisor and Custodian AdministratorState Street Global Advisors Funds Management, Inc. AdvisorSSgA Funds Management, Inc. CustodianState Street Bank and Trust Company DistributorState Street Global Advisors Funds Distributors, LLC Transfer AgentState Street Bank and Trust Company TrusteeN/A Lead Market MakerCitadel Options OptionableOptionable Options Volume12 Put Options0 Call Options12 Short Interest580,412 shs Miscellaneous Outstanding Shares7,200,000Beta0.58 Creation Unit50,000 Creation Fee$250.00 The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free Report Top 10 XPH HoldingsCrinetics Pharmaceuticals (NASDAQ:CRNX)Holding Weight: 3.62%MBX Biosciences (NASDAQ:MBX)Holding Weight: 3.19%Atai Beckley (NASDAQ:ATAI)Holding Weight: 2.82%Definium Therapeutics (NASDAQ:DFTX)Holding Weight: 2.78%Omeros (NASDAQ:OMER)Holding Weight: 2.50%Amylyx Pharmaceuticals (NASDAQ:AMLX)Holding Weight: 2.46%Enliven Therapeutics (NASDAQ:ELVN)Holding Weight: 2.31%Corcept Therapeutics (NASDAQ:CORT)Holding Weight: 2.08%Trevi Therapeutics (NASDAQ:TRVI)Holding Weight: 1.99%Nektar Therapeutics (NASDAQ:NKTR)Holding Weight: 1.97%Full Holdings DetailsXPH Sector ExposureXPH Industry Exposure This page (NYSEARCA:XPH) was last updated on 8/26/2026 by MarketBeat.com Staff. From Our PartnersA $382 trillion migration and the position no one is talking aboutTrump just signed a law requiring America's entire $382 trillion financial system to migrate to a new money ne...Awesomely | SponsoredBezos… DOOMEDA single FCC filing hints Elon Musk is planning his biggest project yet - bigger than Tesla, SpaceX, and X com...Paradigm Press | SponsoredYour book attachedYour Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...Profits Run | SponsoredYour withdrawal order could cost you in taxesIf you have $2M or more saved, the 4% rule points to roughly $92,000 a year - but it's a single-variable answe...SmartAsset | SponsoredThe trade I’ve been waiting for since 2011Ross Givens, Director of Research at Traders Agency, is calling for gold to reach $10,000 an ounce this superc...Traders Agency | SponsoredBuffett's Final Warning: "The Dollar Is Going to Hell"On May 3rd, 2025, Warren Buffett looked at his shareholders for the last time and said: "The dollar is going t...Decentralized Masters | SponsoredWhy acquisitions are reshaping the gold mining sector right nowGold major acquisitions have repriced junior miners overnight, with past deals delivering gains from 40% to 1,...Golden Portfolio | SponsoredTrump’s new dollar decreeThe last time America reset its money, it minted 1,300 new millionaires a day. Porter Stansberry believes Exec...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding SPDR S&P Pharmaceuticals ETF Please log in to your account or sign up in order to add this asset to your watchlist. Share SPDR S&P Pharmaceuticals ETF With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
